Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial | Journal of Neurology, Neurosurgery & Psychiatry

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

JNNP 100

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

This article has a correction. Please see:

Correction: oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial - November 01, 2019

Multiple sclerosis

Research paper

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Olsson T, Boster A, Fernández Ó, et al

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial

Journal of Neurology, Neurosurgery & Psychiatry 2014;85:1198-1208.